Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Liabilities (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Total Liabilities data on record, last reported at $10.4 million in Q3 2025.

  • For Q3 2025, Total Liabilities rose 78.73% year-over-year to $10.4 million; the TTM value through Sep 2025 reached $10.4 million, up 78.73%, while the annual FY2024 figure was $14.8 million, 159.22% up from the prior year.
  • Total Liabilities reached $10.4 million in Q3 2025 per CTNM's latest filing, down from $11.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $97.5 million in Q1 2023 and bottomed at $3.9 million in Q2 2024.
  • Average Total Liabilities over 3 years is $26.0 million, with a median of $11.5 million recorded in 2025.
  • Peak YoY movement for Total Liabilities: crashed 93.26% in 2024, then skyrocketed 198.49% in 2025.
  • A 3-year view of Total Liabilities shows it stood at $5.7 million in 2023, then surged by 159.22% to $14.8 million in 2024, then decreased by 29.8% to $10.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $10.4 million in Q3 2025, $11.5 million in Q2 2025, and $13.5 million in Q1 2025.